Myeloma, also known as plasmacytoma, is the most common malignant tumor of the bone originating from the plasma cells of the bone marrow and is not a benign condition. Myeloma is a malignant tumor caused by the abnormal proliferation of plasma cells. Patients are often over 40 years of age, and the elderly over 60 years of age are the high-incidence group. The main manifestation is persistent progressive aggravation of bone pain, lumbosacral region, chest and limbs are common, and activities can aggravate the pain. Due to the abnormal proliferation of plasma cells in the bone marrow, thus causing extensive bone destruction, patients are often accompanied by fractures, anemia, hypercalcemia, renal function impairment, recurrent infections and other symptoms. Currently, chemotherapy is often used to improve the prognosis of myeloma patients and focus on the prevention and treatment of infection and kidney failure. If the diagnosis of myeloma is confirmed, it is recommended to carry out standardized treatment under the guidance of doctors.